## Stockholder Information 

## COMMON STOCK 

Ticker symbol: BMY New York Stock Exchange 

## ANNUAL MEETING OF STOCKHOLDERS 

Tuesday, May 7, 2013 10:00 a.m. Bristol-Myers Squibb Company 777 Scudders Mill Road Plainsboro, NJ 08536 

## STOCKHOLDER SERVICES 

All inquiries concerning stockholder accounts and stock transfer matters – including address changes, the elimination of duplicate mailings and the Shareowner Services Plus Plan SM – should be directed to the Company’s Transfer Agent and Registrar: 

Wells Fargo Shareowner Services 1110 Centre Pointe Curve, Suite 101 Mendota Heights, MN 55120-4100 

www.shareowneronline.com 

855-598-5485 (within the U.S.) 651-450-4064 (outside the U.S.) 

A telecommunications relay service should be used by the hearing impaired when calling the telephone numbers above. 

## SHAREOWNER SERVICES PLUS PLAN SM 

The Shareowner Services Plus Plan is designed for long-term investors who wish to build share ownership in the Company’s common stock over time. You can participate in the plan if you are a registered holder of the Company’s common stock. If you do not own the Company’s common stock, you can become a participant by making your initial purchase through the plan. The plan features dividend reinvestment, optional cash purchase, share safekeeping, and share sales and transfers. Bristol-Myers Squibb Company has appointed Wells Fargo Shareowner Services as Administrator for the plan. The plan is not sponsored or administered by Bristol-Myers Squibb Company. 

Shareowner Services Plus Plan is a Service Mark of Wells Fargo Shareowner Services. 

## FORM 10-K 

For a free copy of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012, contact: 

Secretary Bristol-Myers Squibb Company 345 Park Avenue New York, NY 10154-0037 

The Form 10-K is also available at investor.bms.com. 

The most recent certifications by the Company’s chief executive officer and chief financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 are filed as exhibits to the Company’s Form 10-K. The Company has also filed with the New York Stock Exchange the most recent Annual CEO Certification as required by Section 303A.12(a) of the New York Stock Exchange Listed Company Manual. 

## ADDITIONAL INFORMATION 

Information on the following subjects is available at www.bms.com: 

• Bristol-Myers Squibb Foundation 

• Clinical Trials 

• Diversity and Workforce Statistics 

• Patient Assistance Programs 

• Political Contributions 

• Sustainability/Environmental Programs 

This Annual Report contains certain forward- looking information within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations and involve inherent risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations. Please see page 27 in the Financial Review for a discussion and description of these risks and uncertainties. The Company undertakes no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise. 

## PRODUCT NAMES AND COMPANY PROGRAMS 

Global products and company programs appearing throughout in italics are referred to herein by their registered and approved U.S. trademarks, unless specifically noted otherwise. 

Abilify  is a trademark of Otsuka Pharmaceutical Co., Ltd. 

Atripla  is a trademark of Bristol-Myers Squibb and Gilead Sciences, LLC. 

Avapro/Avalide  and Plavix  are trademarks of Sanofi. 

Bydureon, Byetta  and Symlin  are trademarks of Amylin Pharmaceuticals LLC and AstraZeneca Pharmaceuticals LP. 

Delestrogen  is a trademark of JHP Pharmaceuticals, LLC. 

Erbitux  is a trademark of ImClone LLC. 

Estrace  and Ovcon  are trademarks of Warner Chilcott Company, LLC. 

Gleevec is a trademark of Novartis AG. 

Humira  is a trademark of AbbVie Biotechnology ltd. 

Reglan  is a trademark of ANIP Acquisition Company. 

Truvada  is a trademark of Gilead Sciences, Inc. 

All other brand names are trademarks of Bristol-Myers Squibb Company or one of its subsidiaries. 

